UNASSIGNED: Previous studies reported inconsistent findings about the relationship between pretreatment @entity1148 and survival in @entity1 with @entity5 . This study aimed to evaluate the prognostic significance of @entity1148 in @entity5 . We searched databases to identify relevant articles. Pooled hazard ratios (HRs), odds ratios (ORs), and 95% confidence intervals (CIs) were calculated. Fourteen studies including 3,394 @entity1 were eligible for the meta-analysis. Overall, an @entity1423 was significantly associated with inferior overall survival (OS, hazard ratio [HR]: 1.66, 95% confidence interval [CI]: 1.42-1.95, P < 0.001) and recurrence-free survival (RFS, HR: 1.67, 95% CI: 1.15-2.42, P = 0.007) but not progression-free survival (PFS, HR: 1.21, 95% CI: 0.89-1.64; P = 0.235). The results were similar for low stage @entity1 treated with surgery alone. Moreover, a pretreatment @entity1148 status was significantly associated with higher clinical stage (odd ratio [OR]: 2.39, 95% CI: 1.68-3.38, P < 0.001), positive pelvic node status (OR: 1.58, 95% CI: 1.01- 2.45, P = 0.044) and larger @entity5 size (OR: 2.32, 95% CI: 1.39-3.87, P = 0.001). Pretreatment @entity1148 is an independent prognosis predictor in @entity5 @entity1 . It may be used as a readily available biomarker to refine clinical outcome prediction for @entity5 @entity1 .

The association of pretreatment @entity1148 with prognosis and clinicopathological significance in XXXX : a systematic review and meta-analysis.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1148 :: ('MESH:D013922', 'Disease') :: ['thrombocytosis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cervical cancer'] @entity1423 :: ('MESH:D001791', 'Disease') :: ['elevated platelet count']
@entity5 :: (MESH:D009369,Disease) :: ['cervical cancer']
